You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK)擬配售本金總額最多8800萬港元可換股債券

格隆匯3月26日丨中國生物科技服務(08037.HK)發佈公吿,2024年3月25日,公司與國元融資(香港)有限公司(作為配售代理)訂立配售協議,據此,公司已委任配售代理,按盡全力基準向不少於6名承配人配售本金總額最多為8800萬港元的可換股債券,該等承配人及其最終實益擁有人為獨立人士第三方。

根據初步換股價每股換股股份0.55港元計算,在可換股債券所附帶的換股權獲悉數行使時,將配發及發行最多1.6億股換股股份,相當於公司現有已發行股本約16.61%及經發行換股股份擴大後的已發行股本約14.24%。初步換股價較3月25日(即配售協議日期)在聯交所所報的收市價每股0.41港元溢價約34.15%。

假設配售協議項下的所有可換股債券均已獲配售,配售事項所得款項總額及淨額估計分別約為8800萬港元及8680萬港元。換股股份的淨價為每股換股股份0.5425港元。公司擬將所得款項淨額約5000萬港元用於投資硼中子捕獲治療項目;及╱或其餘結餘約3680萬港元用於研發成本及集團的一般營運資金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account